HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dermacyte story correction

This article was originally published in The Rose Sheet

Executive Summary

Oxygen Biotherapeutics is planning clinical trials for the use of its Oxycyte technology for OTC products that treat wounds, burns and acne, but is not currently involved in clinical trials, as reported in "The Rose Sheet" Nov. 2, 2009. The firm will seek FDA approval for the applications, after which it hopes to introduce the formulas. Additionally, the Durham, N.C.-based company has been researching the Oxycyte concept in medical indications for 19 years, and has not been working to develop a cosmetic application for that length of time, as reported in the story. "The Rose Sheet" regrets the errors
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS016591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel